Stock Ratings / Health Care / LIVN / forecast

ITGR (67) AXGN (54) TMDX (69) CNMD (62) ⌘ Pro Terminal →

LivaNova PLC (LIVN) 12-Month Stock Forecast & Price Target Cone

$81.25 +0.73% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $81.20

LivaNova PLC (LIVN) carries a Roarable Rating of C- (Hold) with 61/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 61/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.5% avg 90D alpha vs SPY) →

ROARABLE C- • HOLD / WATCH Cap $4.48B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $81.20 (-0.06%)🧬 Cannibal Buyback (-1.24% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 12.5% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 61/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.5% avg 90D alpha vs SPY • 53.9% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C-

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C · Rk C-

Each axis scored 0–20

12M PRICE TARGET CONE+1.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LIVN)Realized 20D OHLCV Swing Band: ±6.1%

Deterministic 5-Pillar Attribution (61/100 Composite)

🔍 WHY LIVN SCORES 61/100 (C-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+16/20 pts (26% of score)

SEC XBRL FY 2025 (10-K): 12.5% FCF Margin ($173.3M FCF) & 67.7% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+12/20 pts (20% of score)

Altman Z-Score 2.21 (WATCH ZONE (1.8–3.0)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning9/20 pts (-11 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-11 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$76.39+1.6% Next Q

Q2 (-2Q)

Grade C$77.58+4.3% Next Q

Q3 (-1Q)

Grade C$80.90+0.4% Next Q

Current

Grade C-$81.25+0.5% Hist 90D α

Trajectory: C- (53) → C- (61)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the LIVN Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 61/100 (C-) score, LIVN faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.24% YoY Shares) — any gross margin slip below 65.2% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($78.49) or 200D SMA ($72.90) invalidates the momentum regime and cuts Target Base ($82.35) toward Bear Floor ($64.23).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LIVN• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “LIVN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 61%NO 39%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your LIVN Position Size: $10,000

Shares at $81.25: 123.1 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $64.23

$7,905

$-2,095 (-20.9%)

12M Consensus BaseTarget $82.35

$10,135

+$135 (+1.4%)

12M Bull Case BreakoutTarget $97.17

$11,959

+$1,959 (+19.6%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (28 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 2

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$86	74%	A
Goldman SachsSector Coverage Lead	BUY	$91	69%	B
JP MorganUS Large-Cap Research	HOLD	$73	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (LIVN Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

LIVN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +35.19%⚡ TESTING RESISTANCE

2026-10-30O $81.38H $82.87L $78.41C $81.25VOL 575.6K

RES: $81.89SUP: $74.07SMA50: $78.49SMA200: $72.90

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LIVN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LIVN Butterfly Map → + Track LIVN →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

13.0%/yr Implied 5Y Growth

vs. +10.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on LIVN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LIVN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for LIVN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LIVN)

Health Care Rank #179 of 1016 ⚔️ ITGR vs LIVN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LIVN vs. ITGR, AXGN, TMDX, CNMD)

Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus (26 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, LivaNova PLC (LIVN) ranks #179 by composite RQD confidence (61/100, grade C-) and #171 by equity capitalization ($4.48B). Within this direct 5-issuer industry benchmark cohort, TMDX leads on earnings valuation at 12.2x trailing P/E, while TMDX leads on capital efficiency and profitability with 18.1% ROIC and 59.9% gross margin. TMDX currently holds the highest overall quantitative score in the immediate peer group at 69/100 (C+) compared with LIVN at 61/100 (C-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
LIVN ACTIVE LivaNova PLC	C-	61/100	—	67.7%	17.3%	+0.73%	$4.48B	Benchmark Subject
ITGR Integer Holdings Corporation	C+	67/100	41.8x	27.0%	6.0%	-0.02%	$4.30B	/itgr-vs-livn →
AXGN Axogen Inc.	D+	54/100	—	74.3%	-2.6%	+0.77%	$2.96B	/axgn-vs-livn →
TMDX TransMedics Group Inc.	C+	69/100	12.2x	59.9%	18.1%	+0.33%	$2.33B	/tmdx-vs-livn →
CNMD CONMED Corporation	C	62/100	28.9x	54.6%	7.8%	-0.09%	$1.36B	/cnmd-vs-livn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001639691

In its most recent audited fiscal period (FY2025, filed 2025-12-31), LivaNova PLC (LIVN) reported GAAP revenue of $1.39B (+10.7% vs. FY2024 revenue of $1.25B , and +20.3% cumulative change since FY2023) , GAAP net income of -$242.5M, operating cash flow of $254.3M, and free cash flow of $173.3M (+27.5% YoY). On the balance sheet, LIVN closed FY2025 with $2.61B in total assets against $345.2M in total debt (Altman Z-Score: 2.21, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$1.39B	-$242.5M	$254.3M	$173.3M	$2.61B	$345.2M
FY2024 (FY)	2024-12-31	$1.25B	$63.2M	$183.0M	$135.9M	$2.51B	$549.6M
FY2023 (FY)	2023-12-31	$1.15B	$17.6M	$74.9M	$74.9M	—	—

3. LIVN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LIVN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, LivaNova PLC (NASDAQ: LIVN) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 61/100 at a spot price of $81.25 (+0.73% 1D, market cap $4.48B). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, LIVN ranks #179 in composite RQD confidence.

How does LIVN compare to ITGR and AXGN in the Health Care sector?

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), LIVN carries a Roarable C- (61/100 RQD), trailing P/E of N/A, gross margin of 67.7%, and ROIC of 17.3%. By comparison, ITGR (Integer Holdings Corporation) holds a C+ grade (67/100 RQD, P/E 41.8x, ROIC 6.0%, cap $4.30B) and AXGN (Axogen Inc.) posts a D+ grade (54/100 RQD, P/E N/A, ROIC -2.6%, cap $2.96B). Among the 5-stock peer group, TMDX leads on earnings multiple (12.2x) while TMDX leads on capital efficiency (18.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for LIVN?

Per LIVN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001639691), LivaNova PLC generated $1.39B in revenue (+10.7% YoY), -$242.5M in net income, and $173.3M in free cash flow against $2.61B in total assets and $345.2M in total debt. Key quantitative strengths: Strong cash generator (68% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is LIVN trading relative to its 50-day, 200-day, and 52-week technical levels?

LIVN last traded at $81.25 (+0.73% on volume of 483,339 shares), positioning the stock +3.52% above its 50-day simple moving average ($78.49) and +11.45% above its 200-day simple moving average ($72.90). Across its 52-week range of $48.82 to $85.76, LIVN sits at the 87.8% percentile with a 14-day RSI of 50.8 (NEUTRAL RANGE) and an implied next-earnings move of ±6.1% ($76.29 to $86.21).

LIVN Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is LIVN's 12-month stock price target?

LivaNova PLC (LIVN) carries a 12-month consensus base price target of $82.35 (+1.4% from $81.25), with a bull-case target of $97.17 and a bear-case floor of $64.23.

Is LIVN stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates LIVN C- (Hold — HOLD) with an RQD Confidence score of 61/100.

Direct Sub-Reports: LIVN RQD Cockpit LIVN 12M Forecast LIVN Earnings & Move LIVN Dividends & DRIP LIVN Insiders & 13F LIVN Whale Options LIVN Profit Sankey LIVN News & Why